LogicFlo AI raises USD $2.7 million to transform life sciences work

LogicFlo AI has secured a seed funding round of USD $2.7 million to support the deployment of its AI agent platform throughout the pharmaceutical, biotechnology, and medical technology sectors.

The Boston-based company, founded by Udith Vaidyanathan and Arun Ramakrishnan, aims to address inefficiencies within life sciences organisations, where highly trained professionals currently spend considerable time on administrative and repetitive tasks, including document formatting, version control, and integrating disparate digital tools.

Funding and deployment

The funding round was led by Lightspeed, with contributions from other healthcare and enterprise AI investors. LogicFlo AI intends to use the new capital to expand its product, increase its workforce, and enhance implementation across global life sciences organisations. The company reports that it already counts a Fortune 500 firm among its clients.

Deployments typically begin with 20 to 30 active users within a team and are designed to scale organically. According to the company, teams have experienced significant improvements, such as reducing medical writing processes previously taking weeks to just minutes, and cutting response times for information requests from up to two weeks to just one or two days.

Platform approach

LogicFlo's platform assigns life sciences experts their own AI agents, which are designed to execute specialised, compliance-focused tasks under human supervision. This model is intended to allow experts to focus on research, regulatory strategy, and driving advancements in medical science, while AI manages repetitive elements of the workload.

"While the rest of the world is focused on automation instead of people, we are building automation for people," said Udith Vaidyanathan, LogicFlo's co-founder and CEO. "LogicFlo puts experts firmly at the centre. The goal is to let the brightest people in life sciences do what only they can do – drive medical science forward and help elevate standard of care."

Vaidyanathan previously held senior roles at Abbott and left Harvard Business School to establish the company. Co-founder and CTO Arun Ramakrishnan formerly led deep learning initiatives at Intuitive Surgical, contributing to AI models for the Da Vinci robotic surgery system.

Ramakrishnan explained LogicFlo's approach: "Traditional automation has failed life sciences because it's too rigid, too brittle, and too out of touch with how people actually work. Our agents are different. They're intelligent, composable, production-ready, and they understand the nuance of scientific work."

Designed for compliance

The system is built for integration in regulated environments, where each AI agent operates within an auditable, human-in-the-loop framework. Agents are designed to adhere to standard operating procedures, company-specific workflows, and compliance templates, only escalating cases to human intervention where necessary. Agents work collaboratively, dividing responsibilities into subtasks, checking outputs, and ensuring quality control throughout the process.

This contrasts with traditional automation approaches and "black-box" AI copilots, which may not offer the same level of transparency or adaptability to regulatory requirements.

Industry applications

LogicFlo's AI agents are deployed across a wide range of life sciences functions. These include medical writing with literature-based content and references, medical communications such as summaries and materials for advisory boards, journal articles, regulatory documents for clinical trial applications, investigational new drugs, safety narratives, and various quality and compliance documents such as standard operating procedures, deviation reports, and corrective actions.

According to LogicFlo, the platform introduces a shift away from traditional systems that primarily store records towards interactive systems where users engage directly with intelligent agents capable of executing tasks and producing reports within a unified environment.

Investment view

Rohil Bagga, VP Investments at Lightspeed, commented: "We're thrilled to back LogicFlo AI as they revolutionise how life sciences and biotech organisations operate. Their AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity. Founders Udith and Arun combine deep domain expertise with exceptional technical acumen - we're excited to support them as they drive transformation in one of the world's most critical industries."

The new funding round will support the expansion of LogicFlo's library of AI agents, improve integrations with widely used life sciences software such as Veeva and IQVIA, and enable further recruitment. The company envisages its platform will contribute to changes in what daily work looks like for scientific professionals by moving tasks forward at a faster pace.

Vaidyanathan concluded: "If we can give scientific experts a platform that moves at their speed, they'll move science forward faster."